Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice

Figure 4

PARP cleavage induced by gemcitabine and rituximab. Cells treated as in figure 2, but for 48 hr with either 2.5 or 5 nM gemcitabine, the cell lysates analyzed by Western using anti-PARP (C2–10, Trevigen, Inc), which detects both intact PARP (116 kD) and the apoptotic marker PARP cleavage fragment (85 kD), or G3PDH as a loading control.

Back to article page